De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

Pluri Beheer

Beheer criteriumcontroles 1/4

De CEO Pluri's is Yaky Yanay, benoemd in Feb2014, heeft een ambtstermijn van 10.33 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 2.75M, bestaande uit 15.1% salaris en 84.9% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 3.07% van de aandelen van het bedrijf, ter waarde € 762.99K. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 3.3 jaar en 2.3 jaar.

Belangrijke informatie

Yaky Yanay

Algemeen directeur

US$2.7m

Totale compensatie

Percentage CEO-salaris	15.1%
Dienstverband CEO	10.3yrs
Eigendom CEO	3.1%
Management gemiddelde ambtstermijn	3.3yrs
Gemiddelde ambtstermijn bestuur	2.3yrs

Recente managementupdates

Recent updates

Analyse CEO-vergoeding

Hoe is Yaky Yanay's beloning veranderd ten opzichte van Pluri's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Mar 31 2024	n/a	n/a	-US$22m
Dec 31 2023	n/a	n/a	-US$24m
Sep 30 2023	n/a	n/a	-US$27m
Jun 30 2023	US$3m	US$414k	-US$28m
Mar 31 2023	n/a	n/a	-US$31m
Dec 31 2022	n/a	n/a	-US$33m
Sep 30 2022	n/a	n/a	-US$36m
Jun 30 2022	US$1m	US$489k	-US$41m
Mar 31 2022	n/a	n/a	-US$47m
Dec 31 2021	n/a	n/a	-US$51m
Sep 30 2021	n/a	n/a	-US$53m
Jun 30 2021	US$9m	US$453k	-US$50m
Mar 31 2021	n/a	n/a	-US$43m
Dec 31 2020	n/a	n/a	-US$37m
Sep 30 2020	n/a	n/a	-US$31m
Jun 30 2020	US$350k	US$303k	-US$29m
Mar 31 2020	n/a	n/a	-US$29m
Dec 31 2019	n/a	n/a	-US$31m
Sep 30 2019	n/a	n/a	-US$34m
Jun 30 2019	US$887k	US$373k	-US$35m
Mar 31 2019	n/a	n/a	-US$37m
Dec 31 2018	n/a	n/a	-US$28m
Sep 30 2018	n/a	n/a	-US$28m
Jun 30 2018	US$443k	US$393k	-US$26m
Mar 31 2018	n/a	n/a	-US$24m
Dec 31 2017	n/a	n/a	-US$30m
Sep 30 2017	n/a	n/a	-US$29m
Jun 30 2017	US$3m	US$253k	-US$28m

Compensatie versus markt: De totale vergoeding ($USD 2.75M ) Yaky } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de German markt ($USD 503.65K ).

Compensatie versus inkomsten: De vergoeding van Yaky is gestegen terwijl het bedrijf verliesgevend is.

CEO

Yaky Yanay (53 yo)

10.3yrs

Tenure

US$2,745,573

Compensatie

Mr. Yaacov Yanay, also known as Yaky, is the Co-Founder of the EyeCue Vision Technologies Ltd. Mr. Yanay has been Chief Executive Officer of Pluri Inc. (formerly Pluristem Therapeutics, Inc.) since June 23...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Yaacov Yanay	President	10.3yrs	US$2.75m	3.07% € 763.0k
Chen Franco-Yehuda	CFO, Treasurer & Secretary	5.3yrs	US$375.24k	0.36% € 89.8k
Lior Raviv	Chief Technology Officer	2.5yrs	geen gegevens	geen gegevens
Efrat Livne-Hadass	Chief Wellbeing Officer	no data	geen gegevens	geen gegevens
Nitsan Halevy	Chief Medical Officer	3.3yrs	geen gegevens	geen gegevens
Nimrod Bar Zvi	Chief Commercial Officer	2.4yrs	geen gegevens	geen gegevens

3.3yrs

Gemiddelde duur

Ervaren management: Het managementteam van 4DX wordt beschouwd als ervaren (gemiddelde ambtstermijn 3.3 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Yaacov Yanay	President	9.3yrs	US$2.75m	3.07% € 763.0k
Doron Birger	Independent Director	2.9yrs	US$45.42k	0.043% € 10.8k
Zami Aberman	Chairman	18.6yrs	US$123.69k	2.45% € 609.4k
James Roosevelt	Member of Advisory Board	less than a year	geen gegevens	geen gegevens
Lorne Abony	Independent Director	less than a year	geen gegevens	0.011% € 2.6k
Yoram Palti	Member of Strategic Advisory Board	2.3yrs	geen gegevens	geen gegevens
Eilon Tirosh	Member of Strategic Advisory Board	2.3yrs	geen gegevens	geen gegevens
Richard Kendall	Member of Scientific Advisory Board	less than a year	geen gegevens	geen gegevens
Maital Shemesh-Rasmussen	Independent Director	3yrs	US$44.00k	0.049% € 12.1k
Prasad Adusumilli	Member of Scientific Advisory Board	less than a year	geen gegevens	geen gegevens
Rami Levi	Independent Director	3yrs	US$40.75k	0.048% € 12.0k

2.3yrs

Gemiddelde duur

70yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van 4DX wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 2.3 jaar), wat duidt op een nieuw bestuur.

Pluri Beheer

Beheer criteriumcontroles 1/4

Belangrijke informatie

Recente managementupdates

Pluri Inc. Announces Executive Changes, Effective September 30, 2024

Pluri Inc., Annual General Meeting, Jun 25, 2024

Pluri Inc. Announces Appointment of Jim Roosevelt, Jr. to its Advisory Board

Pluri Inc. Appoints Andy Lewin to Lead Business of its Contract Development and Manufacturing Organization: PluriCDMO Division

Pluri Inc. Announces Appointment of Lorne Abony to Board of Directors

High number of new and inexperienced directors

Recent updates

Nasdaq Grants Extension Till Nov. 24 to Pluri Inc. to Regain Compliance with Stockholder Equity Requirement

Pluri Inc. Announces Executive Changes, Effective September 30, 2024

U.S. National Institutes of Health Exercises Option to Fund $1.4 Million 2nd Year Budget for Pluri Inc.’s PLX-R18 Acute Radiation Syndrome Contract

Pluri Receives Deficiency Letter from Nasdaq Regarding Non-Compliance with Minimum of $2.5 Million in Stockholders’ Equity Requirement for Continued Listing on the Nasdaq Capital Market

Pluri Inc., Annual General Meeting, Jun 25, 2024

New minor risk - Shareholder dilution

Pluri Inc. Receives First-Ever Patent Approval for 3D Bioreactor Technology in Plant Cell Cultivation

Pluri Inc. Announces Appointment of Jim Roosevelt, Jr. to its Advisory Board

Pluri Inc. has filed a Follow-on Equity Offering in the amount of $10 million.

Second quarter 2024 earnings released: US$0.12 loss per share (vs US$0.24 loss in 2Q 2023)

Pluri Inc. Launches Sustainable Cell-Based Coffee as Countermeasure for Global Coffee Crisis

Pluri Inc. Appoints Andy Lewin to Lead Business of its Contract Development and Manufacturing Organization: PluriCDMO Division

First quarter 2024 earnings released: US$0.12 loss per share (vs US$0.19 loss in 1Q 2023)

Pluri Receives an Extension of an Additional 180 Calendar Days from The Nasdaq Stock Market LLC to Regain Compliance with the Minimum Bid Price Requirement

Full year 2023 earnings released: US$0.77 loss per share (vs US$1.28 loss in FY 2022)

Pluri Inc. Announces PLX-R18 Increases Blood Cell Counts and Reduces Need for Transfusions in Phase I Study: Results Published in Nature Bone Marrow Transplantation

Pluri Inc. Announces Appointment of Lorne Abony to Board of Directors

Pluri Inc. announced that it has received $8.469323 million in funding

Pluri Inc. announced that it expects to receive $8.170972 million in funding

High number of new and inexperienced directors

Pluri Receives Non-Compliance Letter from Nasdaq

Pluri Inc. Announces €7.5 Million Non-Dilutive Grant from the European Union’s Horizon Europe Program to Study PLX-PAD Cells for Osteoarthritis Treatment

Pluristem Reports Topline Results from its Phase III Study of Muscle Regeneration Following Hip Fracture Surgery

Pluristem Therapeutics Inc. Announces Board Changes

High number of new directors

High number of new directors

Pluristem Therapeutics Inc. and Tnuva Group Appoint Eyal Rosenthal as Chief Executive Officer of Their New Joint Venture

High number of new directors

Chairman recently bought €126k worth of stock

Pluristem Therapeutics Inc. Reports Topline Results from its Phase II Studies of Acute Respiratory Distress Syndrome Associated with COVID-19

Independent Director Isaac Braun has left the company

Insider recently sold €1.3m worth of stock

Insider recently sold €84k worth of stock

Pluristem Reports Positive Topline Phase I Results in Innovative Hematology Program, Which Is First to Study PLX-R18 in humans

New 90-day low: €4.30

Revenue in line with expectations

Pluristem Therapeutics Inc. Announces Board Appointments

Pluristem Therapeutics Inc. Enters Collaboration With Innovare R&D to Expand Its ARDS Associated With COVID-19 Program to Mexico

Pluristem Therapeutics Inc. Announces DMC Recommendation Following Interim Analysis of its Phase III CLI Study

New 90-day high: €9.75

Insider recently bought €162k worth of stock

Pluristem Therapeutics Inc. to Present Initial Results from its Phase I HCT Study

New 90-day low: €7.20

Revenue in line with expectations

Insider recently bought €158k worth of stock

Pluristem Announces Clearance to Move Forward with Enrollment for Cohort II in an Investigator-Led Phase I/II Chronic Graft vs Host Disease Study

New 90-day high: €9.40

Pluristem Expands its Phase II COVID-19 European Clinical Trial to Israel

Abu Dhabi Stem Cells Center and Pluristem Unveil Joint Projects At Malta Conferences Foundation Online Event

Insider recently bought €269k worth of stock

Full year earnings released - €1.60 loss per share

New 90-day high - €9.30

Analyse CEO-vergoeding

CEO

Tenure

Compensatie

Leiderschapsteam

Gemiddelde duur

Bestuursleden

Gemiddelde duur

Gemiddelde leeftijd